🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Medical University Of Vienna clinical trials

Source: the EU Clinical Trials Information System (CTIS) — current trials in our EU (CTIS) register with Medical University Of Vienna as lead sponsor. Synced 26 Sep 2026
10Current trials
0Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Medical University Of Vienna is the lead sponsor of 10 current clinical trials in our EU (CTIS) register. The drugs named most often in its trials are Acoramidis, Dexamethasone and Diphenhydramine.

01

Medical University Of Vienna in the EU trials register (CTIS)

10 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Medical University Of Vienna as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
A prospective, randomized, double-blinded, placebo-controlled, cross-over study investigating the effects of metyrapone treatment on cardio-metabolic outcome parameters and chronobiology in patients with mild autonomous cortisol secretion
2026-526837-24-00 · Hormonal diseases
Phase 4 Authorised Austria
An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates
2025-523222-40-00 · Pathological Conditions, Signs and Symptoms
Phase 2 Authorised Austria
Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
2026-526526-41-01 · Cardiovascular Diseases
Phase 4 Authorised Austria
LAFOV-Lung PET
2026-525834-45-00 · CTIS ↗ · Diagnosis
Phase 1 Authorised Austria
Platelet function testing in outpatients after heart transplantation on aspirin therapy
2025-521699-71-01 · CTIS ↗ · Cardiovascular Diseases
Phase 4 Authorised Austria
SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.
2025-525091-29-00 · CTIS ↗ · Surgical Procedures, Operative
Phase 2 Authorised Austria
Direct comparison of Tezepelumab and Dupilumab in CRSwNP in a real world setting
2025-524495-39-00 · CTIS ↗ · Otorhinolaryngologic Diseases
Phase 4 Authorised Austria
Pharmacokinetics of Aztreonam-Avibactam in Critically Ill Patients with Sepsis Receiving ECMO Support: A Prospective PK Study
2025-524614-28-00 · CTIS ↗ · Bacterial Infections and Mycoses
Phase 1 Ongoing Austria
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)
2025-523676-23-00 · CTIS ↗ · Cardiovascular Diseases
Phase 4 Authorised Austria
Venetoclax as treatment of acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation in a Phase-II dose escalation pilot study.
2025-520545-74-00 · CTIS ↗ · Immune System Diseases
Phase 2 Ongoing Austria
02

Drugs in Medical University Of Vienna trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

By trial register

RegisterTrialsRecruiting
EU register (CTIS)10—

A trial with sites in more than one country appears in each of those registers.

04

Questions about Medical University Of Vienna trials

How many clinical trials does Medical University Of Vienna sponsor?

Medical University Of Vienna is the lead sponsor of 10 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Which drugs is Medical University Of Vienna testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Acoramidis (1), Dexamethasone (1), Diphenhydramine (1), Dupilumab (1) and Paracetamol (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.